Event-dense runway: management frames the coming quarters as a calendar of its own named, scheduled events
The model's full reasoning — Q2 2018 call → NOWe need to determine if management frames the near future as a calendar of its own specific, named, already-scheduled events, and treats working through that event sequence as the central story. Let's examine the transcript. Key points from management (Rice Powell and Mike Brosnan): - They discuss Q2 results, but forward-looking statements include: - "We're on track to achieve our 2018 targets." That's general. - "We continue to see progress quarter-to-quarter and we will continue that through the back half of the year." That's general. - "We're probably two quarters in to two to four quarter process in order to get this sorted out with great clarity in detail" regarding Calcimimetics. That's a process, but not a specific event. - "We had a very efficient divestment of Sound." That's past. - "In the ESRD Prospective Payment System draft rule for 2019 came out on July 11... proposed increase of 1.7%... we'll see where we end up in the early days of November as we move to the final draft." That's an external event (CMS rule) but it's a regulatory decision, not a company-specific scheduled event. It's something happening to them. - "We still believe the next stage closing is on track for the second half of this year. You've seen from our press release that we extended the merger agreement out 90 days, we moved it from August 7 to November 5 and we believe that's a viable timeframe for us to see a closure of this business." That's a specific event: closing of NextStage acquisition. That's one event. - "We continue to work with SEC." That's part of that. - "We're on track to deliver on our revenue and net income growth targets." General. Mike Brosnan's forward-looking: - "I would just slightly adjust that guidance... interest... tax rate." That's financial guidance. - "I will provide an update in February with regard to progress we're making and particularly of you towards what we would expect in fiscal 2019 in this area." That's an update, not an event. - "We're continuing to confirm our guidance." General. Other mentions: - "We're going to have to accelerate our growth in the second half. We forecasted and we expect that to happen." That's a general expectation. - "The products franchise is moving solidly to delivering on what we have said they would and the services businesses are accelerating around the globe." General.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| BEAT | BioTelemetry's | Q4 2022 | 2023-03-17 | D |
| ARWR | Arrowhead Pharmaceuticals, Inc. | Q4 2022 | 2022-11-28 | D |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| ALKS | Alkermes plc | Q3 2018 | 2018-10-23 | C |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| DUK | Duke Energy Corporation | Q2 2016 | 2016-08-04 | B |
PCRX · Q4 2017 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management frames the near-term outlook (2018) as a concrete calendar of its own named, time-anchored events—nerve-block label expansion, C-section study readout, additional Phase 4 study launches, CMS reimbursement decisions, and new partnerships—treating the execution of this sequence as the primary driver of 2018 growth and strategic progress. These are presented as scheduled company actions rather than general market trends, with explicit timing (e.g., mid-year FDA meetings, second-half manufacturing ramp, AAOS programs) and positioned as the central story of where the company is heading.
AU · Q2 2018 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management structures the forward outlook around a clear sequence of its own named, time-anchored events—Kibali underground ramp-up and Azambi hydropower station (Q3), Siguiri CIL circuit and power plants (Q4), Obuasi redevelopment milestones (first gold end-2019), Mponeng 6-month backfill plant start (H2), South Africa Section 189 process and wage negotiations (Q3), plus production upticks at multiple sites—presenting these as the primary drivers of the next stage rather than generic market or cost themes.
HROW · Q4 2021 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES The transcript shows management organizing the near-term outlook around a clear sequence of its own named, time-anchored events: AMP-100 PDUFA on October 16 (with launch a few months later), Surface Opthalmics data readout in a few months, Melt Pharmaceuticals top-line data soon after, and internal product 18-month launches, plus MAQ-100 FDA meeting mid-year and relaunch preparations for IOPIDINE/MAXITROL/MOXEZA.